Consensus-based recommendations for the management of juvenile localised scleroderma.
Administration, Oral
Adolescent
Child
Combined Modality Therapy
Consensus
Disease Management
Dose-Response Relationship, Drug
Drug Administration Schedule
Drug Therapy, Combination
Europe
Evidence-Based Medicine
Female
Humans
Male
Methotrexate
/ administration & dosage
Phototherapy
/ methods
Practice Guidelines as Topic
Prednisone
/ administration & dosage
Prognosis
Scleroderma, Localized
/ diagnosis
Severity of Illness Index
Treatment Outcome
DMARDs (biologic)
methotrexate
systemic sclerosis
Journal
Annals of the rheumatic diseases
ISSN: 1468-2060
Titre abrégé: Ann Rheum Dis
Pays: England
ID NLM: 0372355
Informations de publication
Date de publication:
08 2019
08 2019
Historique:
received:
03
11
2018
revised:
17
01
2019
accepted:
13
02
2019
pubmed:
4
3
2019
medline:
13
3
2020
entrez:
4
3
2019
Statut:
ppublish
Résumé
In 2012, a European initiative called Single Hub and Access point for paediatric Rheumatology in Europe (SHARE) was launched to optimise and disseminate diagnostic and management regimens in Europe for children and young adults with rheumatic diseases. Juvenile localised scleroderma (JLS) is a rare disease within the group of paediatric rheumatic diseases (PRD) and can lead to significant morbidity. Evidence-based guidelines are sparse and management is mostly based on physicians' experience. This study aims to provide recommendations for assessment and treatment of JLS. Recommendations were developed by an evidence-informed consensus process using the European League Against Rheumatism standard operating procedures. A committee was formed, mainly from Europe, and consisted of 15 experienced paediatric rheumatologists and two young fellows. Recommendations derived from a validated systematic literature review were evaluated by an online survey and subsequently discussed at two consensus meetings using a nominal group technique. Recommendations were accepted if ≥80% agreement was reached. In total, 1 overarching principle, 10 recommendations on assessment and 6 recommendations on therapy were accepted with ≥80% agreement among experts. Topics covered include assessment of skin and extracutaneous involvement and suggested treatment pathways. The SHARE initiative aims to identify best practices for treatment of patients suffering from PRDs. Within this remit, recommendations for the assessment and treatment of JLS have been formulated by an evidence-informed consensus process to produce a standard of care for patients with JLS throughout Europe.
Identifiants
pubmed: 30826775
pii: annrheumdis-2018-214697
doi: 10.1136/annrheumdis-2018-214697
pmc: PMC6691928
doi:
Substances chimiques
Prednisone
VB0R961HZT
Methotrexate
YL5FZ2Y5U1
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Systematic Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
1019-1024Informations de copyright
© Author(s) (or their employer(s)) 2019. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.
Déclaration de conflit d'intérêts
Competing interests: None declared.
Références
J Pediatr. 2000 Jan;136(1):91-5
pubmed: 10636981
Rheumatology (Oxford). 2002 Oct;41(10):1178-82
pubmed: 12364640
J Rheumatol. 2003 Jan;30(1):193-5
pubmed: 12508412
J Rheumatol. 2003 Sep;30(9):1997-2004
pubmed: 12966605
Dermatology. 2003;207(3):298-301
pubmed: 14571073
Ann Rheum Dis. 2004 Sep;63(9):1172-6
pubmed: 15308532
Leuk Lymphoma. 2005 Jun;46(6):935-9
pubmed: 16019542
Arthritis Rheum. 2005 Sep;52(9):2873-81
pubmed: 16142730
Br J Dermatol. 2005 Oct;153(4):815-20
pubmed: 16181467
South Med J. 2005 Sep;98(9):852
pubmed: 16217974
Rheumatology (Oxford). 2006 May;45(5):614-20
pubmed: 16368732
J Am Acad Dermatol. 2006 Mar;54(3):440-7
pubmed: 16488295
Ann Rheum Dis. 2006 Oct;65(10):1312-24
pubmed: 16707532
J Pediatr. 2006 Aug;149(2):248-51
pubmed: 16887444
Br J Dermatol. 2006 Nov;155(5):1013-20
pubmed: 17034534
Curr Opin Rheumatol. 2006 Nov;18(6):606-13
pubmed: 17053506
Br J Ophthalmol. 2007 Oct;91(10):1311-4
pubmed: 17475707
Rheumatology (Oxford). 2007 Aug;46(8):1316-9
pubmed: 17526926
Rheumatology (Oxford). 2009 Nov;48(11):1410-3
pubmed: 19713439
J Rheumatol. 2009 Dec;36(12):2819-29
pubmed: 19833758
J Rheumatol. 2010 Jan;37(1):175-81
pubmed: 19918041
Rheumatology (Oxford). 2010 Feb;49(2):373-81
pubmed: 20008472
Arthritis Care Res (Hoboken). 2010 Feb;62(2):213-8
pubmed: 20191520
Arthritis Rheum. 2011 Jul;63(7):1998-2006
pubmed: 21305525
Arthritis Care Res (Hoboken). 2011 May;63(5):735-42
pubmed: 21557528
Radiology. 2011 Sep;260(3):817-24
pubmed: 21693661
Int J Dermatol. 2011 Aug;50(8):1006-13
pubmed: 21781079
J Rheumatol. 2012 Feb;39(2):286-94
pubmed: 22247357
Dermatology. 2011;223(4):363-9
pubmed: 22327486
J Paediatr Child Health. 2012 Jul;48(7):572-6
pubmed: 22409322
J Am Acad Dermatol. 2012 Dec;67(6):1151-6
pubmed: 22657157
Pediatr Dermatol. 2012 Nov-Dec;29(6):738-48
pubmed: 23106674
Pediatr Rheumatol Online J. 2013 Feb 15;11(1):5
pubmed: 23414510
AJR Am J Roentgenol. 2013 Apr;200(4):W376-82
pubmed: 23521481
J Am Acad Dermatol. 2013 Aug;69(2):214-20
pubmed: 23562760
Ann Rheum Dis. 2017 Feb;76(2):329-340
pubmed: 27515057
Clin Exp Rheumatol. 2017 Sep-Oct;35 Suppl 106(4):211-213
pubmed: 28980909
Rheumatology (Oxford). 2018 Feb 1;57(2):398-401
pubmed: 29077971
Autoimmun Rev. 2018 Jul;17(7):727-734
pubmed: 29729451
Best Pract Res Clin Rheumatol. 2017 Aug;31(4):576-595
pubmed: 29773274
J Invest Dermatol. 1983 Dec;81(6):517-9
pubmed: 6644093
Arch Dermatol. 1994 May;130(5):663-4
pubmed: 8179352